KRAS and non-small cell lung carcinoma: It demonstrated durable (16.4 months) clinical activity in NSCLC patients KRAS G12C mutant [21], and a current phase 3 trial (NCT03785249) evaluating adagrasib as monotherapy versus docetaxel in KRAS mutant NSCLC patients is ongoing [22].